The Keynote-224 study reported the clinical efficacy of pembrolizumab for second-line treatment of advanced HCC and further analyzed the correlation between the baseline PD-L1 expression level in tumor tissues and the treatment response. The gene discussed is CD274; the disease is hepatocellular carcinoma.